Acetylsalicylic acid (ASA) use among Polish adults with diabetes mellitus

Polskie Archiwum Medycyny Wewnetrznej

Volumn 114, Issue 3, 2005, Pages 862-867

  Drzewoski, Jozef ^a   Sawer Szewczyk, Joanna ^b   Stȩpień, Anna ^a   Olszewski, Andrzej ^b   Liniarski, Marek ^c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b General Hospital   (Poland)

^c Medical Center Skierniewice   (Poland)

Author keywords

Acetylsalicylic acid; Diabetes mellitus; Physician counseling

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CHOLESTEROL;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLAUDICATION; CORONARY ARTERY DISEASE; FAMILY HISTORY; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT DEPARTMENT; PATIENT COUNSELING; POLAND; PREVALENCE; QUESTIONNAIRE; SELF REPORT; STROKE; THROMBOSIS;

EID: 33644759260     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kammel W.B., McGee D.L: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care, 1979, 2, 120.
2. Haffner S.M., Lehto S., Rommemas T., Pyorala K., Laakso M.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339, 229.
3. Fagan T.C., Sowersaw J.: Type 2 diabetes mellitus: greater cardiovascular risk and greater benefits of therapy. Arch. Intern. Med., 1999, 159, 1033.
4. Colwell J.A., Nesto R.W.: The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care, 2003, 26, 2181.
5. Hanson L., Zanchetti A., Carruthers S.G. i wsp.: Effects of intensive blood-pressure lowering and low dose of aspirin on patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 1998, 351, 1755.
6. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA, 1992, 268, 1292.
7. Antiplatelet Trialists Collaboration: Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71.
8. Heart Outcomes Prevention Education (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE substudy. Lancet, 2000, 355, 253.
9. Aspirin therapy in diabetes. Diabetes Care, 2004, 27, S72.
10. Rolka D.B., Fagot-Campagna A., Narayan K.M.V.: Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care, 2001, 24, 197.
11. Aspirin therapy in diabetes (Technical Review). Diabetes Care, 1997, 20, 1767.
12. Krein S.L., Vijan S., Pogach L.M., Hogan M.M., Kerr E.A.: Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care, 2002, 25, 965.
13. Gaede P., Vedel P., Larsen N. et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med., 2003, 348, 383.
14. Egede L.E., Zheng D.: Modifiable cardiovascular risk factors in adults with diabetes. Prevalence and missed opportunities for physician counseling. Arch. Intern. Med., 2002, 162, 427.
15. Montori V.M., Bryant S.C., O'Connor A.M. et al.: Decisional attributes of patients with diabetes: the aspirin choice. Diabetes Care, 2003, 2804, 26.
16. Drzewoski J., Czupryniak L., Saryusz-Wolska M.: Type 2 diabetes mellitus and selected metabolic disorders in urban population aged over 35 years. Pol. Arch. Med. Wewn., 2001, 3, 787.
17. Alter D.A., Khaykin Y., Austin P.C., Tu J.V., Hun J.E.: Processes and outcomes of care for diabetic acute myocardial infarction patients in Ontario. Do physician undertreat? Diabetes Care 2003, 26, 1427.
18. Stafford R.S.: Aspirin use is low among United States outpatients with coronary artery disease. Circulation, 20001, 1097.
19. Collaborative Group of the Primary Prevention Project: low dose asprin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet, 357, 89, 2001.
20. Steering Committee of the Physicians, Health Study Research Group: Final report on the aspirin component of the ongoing Physicians, Health Study. N. Engl. J. Med., 1989, 321, 129.
21. U.S. Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann. Intern. Med., 2001, 136, 157.
22. Sacco M., Pellegrini F., Roncanglioni M.C., Avanzini F., Tognoni G.: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Nicolucci G on behalf of the PPP Collaborative Group. Diabetes Care, 2003, 26, 3264.